NTLA
Intellia Therapeutics Inc
11.80$
-3.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.6% | -3.2% | -5.4% | -1.5% | +1.5% | -17.2% | -8.8% | +2.9% | -9.0% | -9.9% | +13.0% | |
| – | +11.7% | -11.4% | -14.3% | -6.1% | -10.0% | -13.8% | -10.1% | +17.3% | -9.3% | -11.6% | +13.2% | |
| – | +34.9% | -24.2% | -23.9% | -7.9% | +57.0% | -32.9% | +23.1% | +23.8% | -19.6% | -13.4% | -21.2% | |
| – | +6.7% | -13.3% | -12.7% | -4.8% | -8.6% | -16.3% | -8.8% | +11.2% | -12.0% | -16.4% | +16.4% | |
| – | +461.6% | -0.1% | -66.2% | -28.2% | -3.8% | +23.3% | +8.1% | -2.7% | -14.3% | -3.6% | -19.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +21.8% | -10.9% | -1.3% | -4.4% | +51.4% | -35.4% | -11.0% | -3.7% | -3.5% | -19.3% | -6.1% | |
| – | +25.3% | -15.0% | +7.3% | +0.6% | +4.9% | +1.6% | -15.2% | -1.9% | +10.8% | -26.4% | +3.9% | |
| – | +8.9% | +0.9% | +1.1% | +1.1% | +5.6% | +91.5% | -30.4% | +1.4% | -3.3% | -27.9% | +22.3% | |
| – | +109.7% | +83.7% | +37.5% | -30.1% | +11.0% | -15.3% | -20.7% | +35.3% | +52.7% | -7.2% | -37.7% | |
| – | +1.2% | -1.3% | -6.3% | -0.9% | -9.4% | -10.6% | -8.3% | +4.6% | -10.3% | -7.5% | +17.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.0% | +5.6% | +1.5% | +4.2% | +0.8% | +1.6% | +0.2% | +6.2% | -1.6% | +9.3% | +12.7% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.